Thomson Reuters Makes Disease Briefing On Influenza Covering H1n1 (Swine Flu) Publicly Available

Free Access Given to Support the Global R&D and Healthcare Community

Philadelphia, PA, London, UK, In support of the efforts of the global healthcare community working to prevent and address outbreaks such as the current Influenza A (H1N1) flu outbreak, the Healthcare and Science business of Thomson Reuters, the world’s leading source of intelligent information for businesses and professionals, today announced the free availability of its Disease Briefing on Influenza taken directly from the wealth of information and knowledge in Prous Science Integrity®.

The daily briefing can be downloaded from http://science.thomsonreuters.com/pharma/h1n1/, and provides information on Influenza A (H1N1) including:
• Development pipeline for related drugs and vaccines
• Number of laboratory confirmed cases
• International response to the pandemic
• Other critical information resources

The information provided in this disease briefing uses a drug R&D approach designed for life sciences researchers, versus the medical or epidemiological approaches found elsewhere, and focuses on drugs and vaccinations that are currently in the development pipeline or on the market.

Disease Briefings are dynamic executive summaries of the current status and future trends in drug therapy for a specific disease or disorder. They provide key facts on the disease – such as risk factors, prevalence and incidence, morbidity and mortality figures, cost – along with a structured, scientific approach to the drug R&D-related aspects of diagnosis, prevention and treatment.

“Disease Briefings utilize a scientific viewpoint to describing vaccines and drug therapies that are currently under development. This approach accelerates the understanding of the disease and hypotheses to direct new research,” said Jon Brett-Harris, EVP Life Sciences, Thomson Reuters. “It is our hope that making this data freely available will aid researchers and investigators who are responding to this challenge.”

The Prous Science Integrity drug discovery and development portal includes 107 Disease Briefings on diseases and disorders ranging from Acne to Cancer to West Nile Fever. The Disease Briefings are fully integrated into Prous Science Integrity’s suite of scientific information and tools covering the biology, chemistry and pharmacology of drug discovery and development. In Prous Science Integrity, users can link from a Disease Briefing to display the chemical structures and synthesis of the compounds in development to information on the biology of the corresponding drug targets – along with results from preclinical and clinical studies on these compounds.

About Prous Science Integrity
Prous Science Integrity is a unique knowledge solution designed to empower discovery activities right where this is most needed — at the bench. The Prous Science Integrity portal integrates biological, chemical and pharmacological data on more than 300,000 compounds with demonstrated biological activity. For more information, go to http://go.thomsonreuters.com/integrity.

About Thomson Reuters
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.